Université catholique de Louvain and Société de Recherche pour l'Infertilté (SRI), Avenue Grandchamp 143, 1150 Brussels, Belgium.
Pôle de Recherche en Gynécologie, Institut de Recherche Expérimentale et Clinique (IREC), Université catholique de Louvain, Avenue Mounier 52 - B1.52.02, 1200 Brussels, Belgium.
Reprod Biomed Online. 2018 Aug;37(2):216-223. doi: 10.1016/j.rbmo.2018.04.040. Epub 2018 Apr 21.
Ulipristal acetate (UPA), a selective progesterone receptor modulator (SPRM), offers new therapeutic options for the clinical management of large uterine fibroids associated with heavy menstrual bleeding or with other moderate or severe symptoms (bulk symptoms, pelvic pain, decreased quality of life). SPRM are synthetic compounds that exert an agonist or antagonist effect on target tissues by their binding to progesterone receptors. UPA reduces fibroid size, controls bleeding in a high percentage of women and significantly improves quality of life. The present review aims to provide insights into UPA indications and its mechanism of action.
醋酸乌利司他（UPA）是一种选择性孕激素受体调节剂（SPRM），为临床治疗与月经过多或其他中度或重度症状（肿块症状、盆腔疼痛、生活质量下降）相关的大型子宫肌瘤提供了新的治疗选择。SPRM 是通过与孕激素受体结合对靶组织发挥激动剂或拮抗剂作用的合成化合物。UPA 可缩小肌瘤大小，使很大比例的女性出血得到控制，并显著改善生活质量。本综述旨在深入了解 UPA 的适应证及其作用机制。
